1. Introduction {#sec1}
===============

There are more than 200 million global clinical cases of malaria resulting in over 600,000 deaths each year ([@bib28], [@bib40]). In addition to contributing significantly towards overall childhood mortality in the poorest nations, the disease is estimated to cause considerable reduction in economic growth in countries that bear a heavy malaria burden ([@bib13]). The situation is dire because widespread prevalence of drug resistant parasites is making most of the available drugs for treatment to rapidly lose their effectiveness ([@bib14], [@bib31]). Most of the drugs that are currently being used for malaria treatment were developed more than 30 years ago, and many are derivatives of older drugs. Furthermore, only a handful of antimalarials primarily belonging to three main chemical classes (4- and 8-aminoquinolines, antifolates. and artemisinin-based agents) are being used for therapy ([@bib15]). While artemisinin-based combination treatments (ACTs) have played an effective role in controlling the disease in many malaria endemic areas, the appearance of resistant parasites to artemisinin derivatives in wide area of Southeast Asia encompassing south Vietnam to central Myanmar underscores the fragility of malaria treatment measures ([@bib9], [@bib26], [@bib1]). Therefore, there is a pressing need for novel therapeutic options to treat resistant malaria. Historically, natural products were the most important source for the majority of therapeutics, including antimalarials ([@bib25]). Quinine and artemisinin and their synthetic derivatives are prime examples in the malaria field ([@bib39], [@bib21]). Current trends in lead discovery are biased towards high-throughput screening (HTS) of synthetic compound collections instead of the testing of natural products (NPs). The complexity of natural product structures are often accompanied by synthetic challenges and supply problems, whereas compound collections of commercial sources or "in-house" origin are easily accessible. Nevertheless, because NPs are known to occupy biologically important chemical space, they continue to be valuable for the discovery of new biologically active compounds. The synthesis of NP-inspired compound libraries is a promising alternative covering chemical space similar to NPs while being synthetic tractable ([@bib7], [@bib32], [@bib36]). Critical evaluation of known drugs and NPs has been used to identify NP-based substructural motifs, termed as "BioCores" ([@bib22]), which have been incorporated into the scaffolds of a BioDesign synthetic library to increase drug-likeness of compounds. In an effort to identify novel antimalarial scaffolds we have screened a subset of the anti-infective BioDesign collection of the vendor Asinex that incorporates "BioCore" features and structures (e.g., enriched oxygen and saturated rings), which were filtered against peroxide bridges that are present in many current antimalarials. Herein, we report that spirocyclic chromane compounds demonstrate potent antiplasmodial activities with excellent selectivity. Furthermore, we demonstrate that this chemotype exhibits a cellular mechanism of action distinct from current antimalarials.

2. Materials and methods {#sec2}
========================

2.1. Plasmodium falciparum culture and EC~50~ determination {#sec2.1}
-----------------------------------------------------------

*Plasmodium falciparum* Dd2 and 3D7 strains were maintained at 37 °C in 5% CO~2~ and 95% air using a modified Trager and Jensen ([@bib35]) method in RPMI media with [l]{.smallcaps}-glutamine (Invitrogen) and supplemented with 25 mM HEPES, 26 mM NaHCO~3~, 2% dextrose, 15 mg/L hypoxanthine (Sigma--Aldrich), 25 mg/L gentamicin (Life Technologies), and 0.5% Albumax II (Life Technologies). Different dilutions of the compound in RPMI 1640 (Life Technologies) from a stock of 10 mM in dimethyl sulfoxide (DMSO) were added to the culture at a 1% parasitemia and 2% hematocrit in 96-well black plates (Santa Cruz Biotechnology). Maximum DMSO concentration in the culture never exceeded 0.125%. Chloroquine at 1 μM was used as a positive control to determine the baseline value. Following 72 h incubation at 37 °C, the ability of the compounds to inhibit growth of the parasite was determined by a SYBR green I-based DNA quantification assay ([@bib4], [@bib33], [@bib19]). EC~50~ was calculated (n = 3) from a dose response curve that was generated from a concentration range of 0--20 μM using GraphPad Prism v5.0.

2.2. Cytotoxicity determination {#sec2.2}
-------------------------------

Compounds were evaluated for cytotoxicity using HepG2 human hepatoma cells. A 384-well clear bottom plate (Santa Cruz Biotechnology) was seeded with 2500 cells/well and incubated for 24 h. Serial dilutions (0--40 μM concentration range) of the compound were added to the plate followed by incubation for an additional 48 h. Viability of cells were assessed by MTS \[(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) cell proliferation assay (CellTiter 96® Aqueous non-radioactive cell proliferation assay, Promega) ([@bib8]).

2.3. Physicochemical parameters {#sec2.3}
-------------------------------

The aqueous solubility at pH 7.4 was determined by UV--visible absorption based method ([@bib2]). The permeability was assessed by the *in vitro* double-sink parallel artificial membrane permeability assay ([@bib20]) that is a model for the passive transport from the gastrointestinal tract into the blood stream. The microsomal stability ([@bib18]) was determined in the presence of mouse liver microsomes with or without NADPH.

2.4. Determination of cellular mechanism of action {#sec2.4}
--------------------------------------------------

*P*. *falciparum* Dd2 cultures were tightly synchronized using a combination of magnetic separation of schizonts ([@bib30]) followed by sorbitol treatment at the early ring stage ([@bib24]). Inhibitory effects of UCF 201 on parasite development, merozoite egress and invasion were analyzed by treating the synchronized culture (1.5% hematocrit and 5% parasitemia) at four different time-points post-merozoite invasion (6, 18, 30, and 42 h post invasion or hpi) at 5×EC~50~ final concentration for a duration of 36 h (or 24 h for treatments at the 42 hpi) under regular culture conditions. Giemsa-stained thin smears were prepared at 12 h intervals for microscopic evaluations of the intraerythrocytic maturation of parasite.

2.5. Synthesis of spirocyclic chromane UCF 201 {#sec2.5}
----------------------------------------------

In order to meet the amount of compound needed for *in vivo* efficacy studies, hit compound UCF 201 has been prepared "in-house" ([Fig. 1](#fig1){ref-type="fig"}). Compound **1** was synthesized via an acetylation of α-naphthol using hot glacial acetic acid and zinc chloride ([@bib37]). It was then converted to compound **2** by refluxing with *tert*-butyl 4-oxopiperidine-1-carboxylate and pyrrolidine in methanol, which was then deprotected in dichloromethane using trifluoroacetic acid to afford compound **3**. Compound **3** was then reacted with epoxide **4**, which was obtained from the sulfur-ylide epoxidation of 3,4-difluorobenzaldehyde in ethanol, to yield compound **5** which was subsequently converted to UCF 201 using sodium borohydride in absolute ethanol.

***tert*-butyl 4-oxo-3,4-dihydrospiro\[benzo\[h\]chromene-2,4\'-piperidine\]-1\'-carboxylate (2):** A solution of intermediate **1** ([@bib37]) (500 mg, 2.7 mmol), *tert*-butyl 4-oxopiperidine-1-carboxylate (536 mg, 2.7 mmol) and pyrrolidine (517 mg, 7.2 mmol) in absolute methanol (5 mL) was refluxed for 8 h under N~2~. The methanol was removed under reduced pressure and the residue was purified by flash chromatography (hexanes:EtOAc = 7:1) to afford **2** (908 mg, 92%) as a yellow solid. R~f~ (hexanes:EtOAc = 5:1) = 0.37. ^1^H NMR (400 MHz, CDCl~3~) δ: 8.40--8.24 (m, 1H), 7.84 (d, *J* = 8.7 Hz, 1H), 7.82--7.76 (m, 1H), 7.65--7.59 (m, 1H), 7.58--7.50 (m, 1H), 7.40 (d, *J* = 8.6 Hz, 1H), 3.97 (d, *J* = 13.5 Hz, 2H), 3.42--3.19 (m, 2H), 2.82 (s, 2H), 2.29--2.14 (m, 2H), 1.70 (s, 2H), 1.47 (s, 9H) ppm. ^13^C NMR (101 MHz, CDCl~3~) δ: 191.19, 157.06, 154.78, 137.89, 129.76, 128.14, 126.51, 125.36, 123.24, 121.55, 121.00, 115.20, 79.99, 79.16, 47.80, 39.55, 34.29, 28.55 ppm.

**spiro\[benzo\[*h*\]chromene-2,4\'-piperidin\]-4(3*H*)-one (3):** A stirred solution of **2** (1.5 g, 4.0 mmol) in DCM (40 mL) was cooled to 0 C TFA (13 mL) was then added drop wise and the reaction mixture was allowed to warm to room temperature. After 2 h, the reaction was diluted with water (40 mL) and extracted with DCM (40 mL×2). The aqueous layer was basified to pH 9.0 with 10% NaOH and then extracted with DCM (40 mL×3). The organic layer was combined, dried with sodium sulfate and concentrated under reduced pressure to afford **3** (1.05 g, 97%) as a brown solid). R~f~ (DCM:MeOH = 10:1) = 0.3. ^1^H NMR (600 MHz, CDCl~3~) δ: 8.37 (d, *J* = 8.4 Hz, 1H), 7.82 (d, *J* = 8.7 Hz, 1H), 7.77 (d, *J* = 8.1 Hz, 1H), 7.62--7.58 (m, 1H), 7.55--7.50 (m, 1H), 7.37 (d, *J* = 8.6 Hz, 1H), 3.21--3.12 (m, 2H), 2.98--2.90 (m, 2H), 2.80 (d, *J* = 1.5 Hz, 2H), 2.22--2.13 (m, 2H), 2.08 (s, 2H), 1.77--1.67 (m, 2H) ppm. ^13^C NMR (151 MHz, CDCl~3~) δ: 191.66, 157.29, 137.85, 129.63, 128.04, 126.32, 125.49, 123.44, 121.54, 120.67, 115.14, 79.62, 48.17, 42.13, 35.36 ppm. HRMS (ESI) calcd for C~17~H~18~NO~2~ \[M+H\]^+^: 268.1332, found: 268.1325.

**2-(3,4-difluorophenyl)oxirane (4):** Potassium hydroxide pellets 3.92 mg, 7.0 mmol) was added to a solution of 3,4-difluorobenzaldehyde (500 mg, 3.5 mmol) and trimethylsulfonium iodide (Me~3~SI) (1.1 g, 5.4 mmol) in acetonitrile (8 mL) and water (20 μL). The mixture was stirred at 80 °C for 4 h and then cooled; the acetonitrile was removed by rotatory evaporator. The residue was treated with a solution of water (20 mL) and sodium hypochlorite or bleach (5 mL) followed by extraction with diethyl ether (15 mL×3). The organic layer was combined, dried with sodium sulfate and the solvent was removed under reduced pressure. The crude was used without further purification.

**1\'-(2-(3,4-difluorophenyl)-2-hydroxyethyl)spiro\[benzo\[h\]chromene-2,4\'-piperidin\]-4(3*H*)-one (5):** A solution of **3** (500 mg, 1.8 mmol) and **4** (292 mg, 1.8 mmol) in ethanol (30 mL) was heated to reflux for 18 h. The ethanol was removed under reduced pressure and the residue was purified by flash chromatography (hexanes:EtOAc = 2:1) to afford **5** (498 mg, 63%) as a yellow solid. R~f~ = 0.69 in EtOAc. ^1^H NMR (600 MHz, CDCl~3~) δ: 8.34 (d, *J* = 8.3 Hz, 1H), 7.85 (d, *J* = 8.6 Hz, 1H), 7.80 (d, *J* = 8.1 Hz, 1H), 7.65--7.60 (m, 1H), 7.55 (t, *J* = 7.6 Hz, 1H), 7.40 (d, *J* = 8.7 Hz, 1H), 7.25--7.21 (m, 1H), 7.15--7.09 (m, 1H), 7.08 (d, *J* = 3.4 Hz, 1H), 4.73--4.69 (m, 1H), 2.97 (t, *J* = 11.4 Hz, 1H), 2.93--2.86 (m, 1H), 2.83 (d, *J* = 16.1 Hz, 2H), 2.72--2.59 (m, 3H), 2.49--2.43 (m, 1H), 2.31--2.22 (m, 2H), 1.92--1.81 (m, 2H) ppm. ^13^C NMR (151 MHz, CDCl~3~) δ: 191.39, 157.16, 150.6 (dd, *J* = 249.0, 16.2 Hz), 149.8 (dd, *J* = 248.2, 12.7 Hz), 139.30 (dd, *J* = 5.3, 3.5 Hz), 137.93, 129.72, 128.17, 126.43, 125.47, 123.32, 121.75 (dd, *J* = 6.3, 3.5 Hz) 121.63, 120.91, 117.22 (d, *J* = 17.2 Hz), 115.26, 114.95 (d, *J* = 18.0 Hz), 78.79, 68.07, 66.19, 50.63, 47.86, 47.73, 34.78, 34.60 ppm. HRMS (ESI) calcd for C~25~H~24~F~2~NO~3~ \[M+H\]^+^: 424.1719, found: 424.1705.

**1\'-(2-(3,4-difluorophenyl)-2-hydroxyethyl)-3,4-dihydrospiro\[benzo\[h\]chro-mene-2,4\'-piperidin\]-4-ol (**UCF 201): Sodium borohydride (27 mg, 0.7 mmol) was added to a solution of **5** (100 mg, 0.23 mmol) in absolute ethanol (2 mL). The reaction mixture was heated at reflux overnight and then cooled. The ethanol was removed under reduced pressure, the residue was diluted with water (2 mL) and extracted with ethyl acetate (5 mL×3). The combined organic layer was dried with sodium sulfate, the solvent was evaporated and the residue was purified by flash chromatography (DCM:MeOH = 30:1) to afford final compound **1** (88 mg, 88%) as a white solid. R~f~ (DCM:MeOH = 10:1) = 0.37. ^1^H NMR (600 MHz, CDCl~3~) δ: 8.30--8.18 (m, 1H), 7.83--7.70 (m, 1H), 7.57--7.44 (m, 3H), 7.46--7.34 (m, 1H), 7.26--7.20 (m, 1H), 7.15--7.08 (m, 1H), 7.08--7.02 (m, 1H), 4.93 (t, *J* = 6.7 Hz, 1H), 4.78--4.59 (m, 1H), 2.99--2.73 (m, 2H), 2.74--2.50 (m, 3H), 2.49--2.35 (m, 1H), 2.22--2.05 (m, 2H), 2.02--1.88 (m, 2H), 1.88--1.62 (m, 2H) ppm. ^13^C NMR (151 MHz, CDCl~3~) δ: 150.53 (dd, *J* = 247.1, 13.6 Hz), 149.73 (dd, *J* = 248.6, 13.5 Hz), 147.46, 139.43 (dd, *J* = 4.9, 3.5 Hz), 134.37, 127.68, 126.64, 125.60, 125.49, 125.47, 122.12, 121.75 (dd, *J* = 6.4, 3.3 Hz), 120.22, 117.97, 117.14 (d, *J* = 17.2 Hz), 114.90 (d, *J* = 17.8 Hz), 73.90, 73.88, 67.95, 66.23, 63.33, 50.89, 50.75, 47.92, 47.78, 41.99, 36.10, 35.84, 34.47, 34.19 ppm. HRMS (ESI) calcd for C~25~H~26~F~2~NO~3~ \[M+H\]^+^: 426.1875, found: 426.1861.

2.6. Cytological profiling of inhibition mechanisms {#sec2.6}
---------------------------------------------------

Effects of UCF 201 on merozoite egress and invasion were analyzed using a recently reported high content image-based assay for malaria parasitemia detection and stage classification in a 384-well format ([@bib27]). Sorbitol synchronized cultures (*P*. *falciparum* HB3 infected cultures) at 1.5% hematocrit and 5% parasitemia were treated at 42 h post-merozoite invasion with UCF 201 or reference compounds (N-acetylglucosamine (GlcNAc), E-64, or artemisinin) each at 10 μM final concentration for a duration 24 h under a culture condition of 37 C in gassed chambers (5% CO~2~, 1% O~2~ and 94% N~2~). The cultures were then diluted in a staining solution comprising wheat germ agglutinin-Alexa Fluor 488 conjugate and Mitotracker Red CMXRos each at 1 nM final concentrations, and maintained for 20 min at 37 C to allow for complete incorporation of the dyes. The cultures were further diluted to a final hematocrit of 0.02% in a fixing solution comprising 4% paraformaldehyde and 5 μg/ml DAPI and left to stand at room temperature for 10 min. Following a brief vortex at 1700 rpm for 45 s, and a short spin at 1000 rpm for 1 min, five image fields were captured using the Operetta 2.0 automated imaging system (Perkin Elmer) from each assay well (384-well glass plate, Matrical) with a 40X high numerical aperture objective. Operetta automated high content imaging system is equipped with a 50 μM pinwheel array and images were captured at three wavelengths (405 nM, DAPI; 488 nM, Alexa fluor; and 635 nM, Mitoracker deep red).

2.7. Flow cytometric profiling of inhibition {#sec2.7}
--------------------------------------------

Synchronized *P*. *falciparum* Dd2 cultures were treated (5×EC~50~) with UCF 201 at 6 hpi, samples were collected at 18, 30, 42, and 54 hpi time intervals, fixed in a solution containing 0.04% glutaraldehyde in PBS, permeabilized with 0.25% Triton X-100, treated with RNAse (50 μg/ml) and stained with 10.24 μM YOYO-1 ([@bib6]). Flow cytometry acquisition was performed in BD Accuri C6 using FL-1 channel (488 nm Laser with 533/30 filter).

2.8. In vivo efficacy of UCF 201 {#sec2.8}
--------------------------------

Female pathogen-free Balb/c mice (8 weeks old, ∼25 g, 5 animals per group) were infected with 1 × 10^6^ *P*. *berghei* ANKA parasitized RBC (from a donor mouse) by intraperitoneal injection. UCF 201 was formulated in 0.5% hydroxyethylcellulose-0.1% Tween 80 for oral delivery (0.2 ml/dose). The control group had vehicle only. Parasitemia was monitored by microscopic evaluations of Giemsa-stained thin smears of daily superficial temporal vein bleed samplings. This animal study protocol was approved by the Institutional Animal Care and Use Committee at the University of Central Florida.

3. Results and discussion {#sec3}
=========================

To identify novel compounds that interact with cellular targets different from those of current antimalarials, we screened a 594 compound collection containing NP-like structural motifs (e.g. alkaloids, stereogenic carbons, sp^3^-rich frameworks, basic nitrogens and others) lacking the presence of a peroxide bridge (which is typical for the artemisinin class of antimalarials) from a natural BioDesign scaffold library. To the best of our knowledge, no report of screening of such a compound selection for antimalarial activities exists. We used an unbiased cell-based screen utilizing SYBR green I-based DNA quantification assay ([@bib4], [@bib33], [@bib19]) to identify antiplasmodial activities. For our primary screen, we used the chloroquine-resistant Dd2 strain, as our main goal was to overcome the problem of drug-resistant malaria. For selecting initial hits, we used a stringent criteria of \>75% inhibition of the parasite growth at 1 μM. We identified 98 (16%) initial hits from 22 different scaffolds based on this criterion. The half maximal effective concentration (EC~50~) values of hits prioritized by this criteria were determined against both the chloroquine-resiatnt (Dd2) and chloroquine-sensitive (3D7) strains. UCF 201, which contains two unique structural elements consisting of a chromane ring and a spirocyclic carbon center belongs to the compound class of spirocyclic chromanes, exhibited antiplasmodial potency with an EC~50~ value of 350 nM ([Table 1](#tbl1){ref-type="table"}) was among the most active compounds. Furthermore, this chemotype showed similar or better EC~50~ values with the chloroquine resistant Dd2 strain compared to the chloroquine sensitive 3D7 line, indicating that it is not influenced by the efflux mechanism of PfCRT of chloroquine-resistant strains ([@bib11]). The cytotoxicity of UCF 201 was determined in human HepG2 hepatoma cells using the MTS cell proliferation assay. The EC~50~ value of UCF 201 in HepG2 cells was 19 μM suggesting an excellent selectivity of over 50-fold ([Table 1](#tbl1){ref-type="table"}).

UCF 201 is in compliance with Lipinski\'s parameters. The data as shown in [Table 2](#tbl2){ref-type="table"} suggest that the properties of this compound are in line with the preferred parameters in respect of distribution coefficient (clogP), molecular weight, number of hydrogen bond donors and acceptors, as well as polar surface area. We next determined the *in vitro* physiochemical profiles of the compound. The aqueous solubility of UCF 201 was moderate at pH 7.4 with a value of 24.3 μg/ml (57.1 μM), and even better at lower pH. UCF 201 also exhibited excellent permeability (logPe of \<−2.9) compared to reference compounds as assessed by the *in vitro* double-sink parallel artificial membrane permeability assay ([@bib20]) that is a model for the passive transport from the gastrointestinal tract into the blood stream. The microsomal stability ([@bib18]) of UCF 201 in the presence of mouse liver microsomes is low (16% remaining at 60 min). Measurements from the aforementioned assays provided initial evidence that the spirocyclic compound UCF 201 displayed acceptable physiochemical profiles.

In order to perform an expedient SAR evaluation on various skeleton motifs of UCF 201, we chose related analogues from Asinex\'s compound collections. We tested spirocyclic analogues (**6**--**21**) with an emphasis on the substitutions of the piperidine nitrogen and the results are summarized in [Table 1](#tbl1){ref-type="table"}. An important observation from this limited SAR reveals that simple phenyl derivatives are much more tolerated than large aromatics such as indoles and naphthalenes in terms of potency. Within the selected phenyl groups, it seems that electron density plays no significant role for antimalarial activities as the EC~50~ values of the electron-poor UCF 201 and the electron-rich analogue **7** are only marginally different from their reference counterpart **6**. Mono-fluoro analogue **13** shows an inferior potency profile to electron-rich analogues; however, additional fluorine atom boosts the potency by almost two folds, which indicates that the lipophilicity, rather than the electron density, may have a significant impact on the EC~50~. Our study also suggests that the benzo\[*h*\]chromane of UCF 201 may be replaced by a simple chromane scaffold without sacrificing submicromolar antimalarial activity. Because the role of naphthalene on piperidine nitrogen could not be determined by the current SAR study, a thorough screening with phenyl-derived chromanes is necessary to better understand such structural features.

To further define the stage-specificities and speeds of action of UCF 201, we investigated its effects on (i) schizont development, and (ii) merozoite egress and invasion processes. In this assay, we treated synchronized cultures with UCF 201 at different stages of intraerythrocytic developmental cycle and followed its effect on parasite development by quantifying culture parasitemias, and proportions of each parasite stage in culture (early rings, mid-late rings, trophozoites, and schizonts) microscopically. As can be seen from [Fig. 2](#fig2){ref-type="fig"}, while the control culture matures through the developmental cycle, UCF 201 blocks maturation. UCF 201 was early acting in inhibiting intraerythrocytic developmental cycle when added at either the early ([Fig. 2](#fig2){ref-type="fig"}A 6 h post invasion) or late ([Fig. 2](#fig2){ref-type="fig"}B, 18 h post invasion) ring stages. UCF 201 also exhibited inhibitory activity against schizont development from the mid-trophozoite stage (30 hpi) ([Fig. 2](#fig2){ref-type="fig"}C). In addition, when added at the late schizont stage (42-hpi), UCF 201 displayed notable reductions in culture parasitemias with increased accumulation of free merozoites not schizonts in the culture ([Fig. 3](#fig3){ref-type="fig"}A and B). Artemisinin was used as a reference antimalarial compound acting on asexual stages and E-64, a cysteine protease inhibitor, blocking egress ([@bib5]). As expected artemisinin exposure at 42 hpi did not block merozoite egress or invasion, whereas E-64 treatment blocked egress as evidenced by presence of intracellular schizont. Detection of extracellular merozoites ([Fig. 3](#fig3){ref-type="fig"}B) suggests an inhibitory effect of UCF 201 on the merozoite invasion process in a manner similar to that of the reference invasion inhibitor N-acetylglucosamine ([@bib17]). Additionally, we conducted a flow cytometric analysis of the synchronized parasite culture following exposure to UCF 201. The 6 hpi culture at the ring stage was treated with UCF 201 at 5×EC~50~ and aliquots were withdrawn at 12 h intervals for flow cytrometric analysis following staining with YOYO-1 dye. As shown in [Fig. 3](#fig3){ref-type="fig"}C, the peaks on the right in control culture at 6 hpi represent singly, double or triply-infected RBC based on DNA content. Following maturation of the parasite the peaks merge as DNA content increases. At 42 hpi peaks begin to reappear as reinvasion occurs. At 54 hpi parasites are at the ring stage of the next growth cycle, peak height increases, and individual peaks reappear. In contrast, exposure to UCF 201 and artemisinin at the ring stage of maturation is blocked. Collectively, the above data suggest that UCF 201 may act by inhibiting parasite target(s) that are common to all major intra-erythrocytic forms of *P*. *falciparum*.

To overcome the problems of drug-resistance in malaria, a major goal is to identify the next-generation of lead compounds that are acting early on parasite\'s developmental cycle with novel mechanism of action. The majority of the current antimalarial drugs target the digestive vacuole, mitochondrial electron transport chain, or apicoplast processes of the parasite ([@bib3], [@bib12], [@bib23], [@bib10]). Recent analysis of 10 widely used antimalarials show that none of the drugs were active in blocking merozoite invasion, whereas only artemisinin and artesunate demonstrated significant ring stage activity ([@bib38]). A major significance of our work is that the spirocyclic chromane scaffold inhibits early cellular processes of the parasite invasion as well as all development stages of the asexual development of the parasite. Activity of UCF 201 against the ring stage is noteworthy given that latent ring stage has been shown to promote *in vitro* resistance to dihydroartesunate ([@bib16], [@bib34]). Inhibitory effect of UCF 201 against all stages of asexual life cycle of the parasite ([Fig. 2](#fig2){ref-type="fig"}A and B) makes it particularly useful for the treatment of acute infection where rapid clearance is needed. Because UCF 201 acts on all intraerythrocytic developmental forms including rings and merozoites, we can predict that the spirocyclic chromane chemotype action is likely to be distinct from known antimalarial compounds.

Our evaluation of *in vivo* antimalarial efficacy of UCF 201 using the murine malaria model infected with *P*. *berghei* ANKA strain demonstrated that the compound prolonged survivability \>1.7 times (12 versus 7 days) compared to the control and delayed the increase in parasitemia ([Fig. 4](#fig4){ref-type="fig"}). The *P*. *berghei* mouse model is quite demanding; requires total clearance of parasites otherwise fatal parasitaemia recrudesce ([@bib29]). However, these results are the proof-of-concept of the utility of spirocyclic chromanes for malaria therapy. Given that this novel antiplasmodial scaffold exhibits excellent selectivity, acceptable physicochemical properties and broad activity on asexual developmental stages, we believe it will be a good candidate for hit to lead optimization.
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==============================
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![Synthetic Scheme of UCF 201. Starting from commercially available α-naphthol, UCF 201 was synthesized in 6 steps in good yields.](gr1){#fig1}

![Activity Profile of UCF 201 on P. falciparum Asexual Stages. The effect of UCF 201 on parasite life cycle stage progression upon treatment at (A) 6 h, (B) 18 h, or (C) 30 h post-invasion time-points at 5×EC~50~ for 36 h. For the (D) 42 h post-invasion time-point the effect was followed for 24 h after compound addition. Giemsa-stained thin smears were prepared at 12 h intervals for microscopic evaluations. Microscopic images represent parasite stages after evaluating 1000 infected RBC.](gr2){#fig2}

![(A) Effect of UCF 201 on Parasitemia When Treated at the Late Schizont/Segmenter Stage. Synchronized culture at 42 h post invasion was treated with 5×EC~50~ of the compound. Giemsa stained thin smears were prepared every 12 h for microscopic evaluations of parasitemia to quantify parasitemia. (B) Confocal plate micrograph of parasite phenotype following 24 h exposure at 42 hpi. Synchronized cultures were exposed to UCF 201 or reference compounds E-64, GlcNac, or artemisinin at 10 μM concentration. (C) Effect of UCF 201 on P. falciparum growth by flow cytometric analysis of YOYO-1 labeled cells. The synchronized culture was exposed to UCF 201 at 6 hpi with 5×EC~50~ of UCF 201. Plots represent cell count in y-axis versus FL1 channel representing DNA content.](gr3){#fig3}

![Efficacy of UCF 201 in the Mouse Malaria Model. (A) Effect of UCF 201 on the survivability of P. berghei ANKA infected Balb/c mice. (B) Effect of UCF 201 on increase in parasitemia in the P. berghei ANKA infected mice. The experiments were conducted according to the approved protocol of UCF IACUC committee.](gr4){#fig4}

###### 

Activity of the Spirocyclic Chromane Chemotype. Z' factors of these assays were \>0.8. For the antimalarial screening different dilutions of compounds were added to an asynchronous culture at a 1% parasitemia and 2% hematocrit and incubated at 37 °C for 72 h. Each assay was done in triplicate and repeated at least 3 times (n = 3) and the standard deviation of values are shown. For the cytotoxicity assessment the incubation time with compounds was 48 h.
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###### 

Physicochemical properties of spirocyclic chromane UCF 201.

  Property                                            UCF 201
  --------------------------------------------------- ----------------
  clogP                                               3.85
  Molecular Weight (g/mol)                            425.5
  Number of H Bond Donor                              2
  Number of N & O Atoms                               4
  Polar Surface Area (A^2^)                           52.9
  Aqueous Solubility pH 7.4/6.2/5.0(μg/mL)            24.3/\>42/\>42
  Permeability pH 7.4/6.2/5.0 (−logPe)                \<2.9/3.2/3.6
  Mouse Microsome Stability (% remaining at 60 min)   15.6

Guidelines:

Aqueous solubility: \<10 μg/ml-low; 10--60 μg/ml-moderate; \>60-high Reference permeability (−logPe) at pH 7.4/6.2/5.0: Verapamil-HCl -2.7/2.9/3.7; metoprolol- 3.6/4.4/\>5.4; rantidine- \>5.9/5.1/5.2. Verapamil-HCl is considered highly permeable, metoprolol is moderately permeable; and rantidine is poorly permeable. Reference microsomal stability (% remaining at 60 min): Verapamil- 68.8%; Testosterone- 26.1%
